|
Neoplasm Metastasis
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Additionally, a negative correlation between miR‑29a and REV3L mRNA expression levels in tumor tissues from patients with NSCLC was observed; low expression of miR‑29a and high expression of REV3L were closely associated with an advanced tumor‑node‑metastasis classification.
|
30535450 |
2019 |
|
Squamous cell carcinoma of esophagus
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of miR-145 decreased REV3L mRNA and protein level in ESCC cell line KYSE150, while decreased miR-145 increased REV3L mRNA and protein level in esophageal epithelium cell line (HEEC).
|
31072625 |
2019 |
|
Carcinomatosis of peritoneal cavity
|
0.010 |
Biomarker
|
disease |
BEFREE |
Two examples of the potential broad clinical applicability of this concept in a mouse xenograft model of ovarian cancer peritoneal carcinomatosis are provided: silencing the Rev3l subunit of polymerase Pol ζ to impair DNA repair in combination with cisplatin; and reprogramming tumor-associated macrophages into a proinflammatory state.
|
31267590 |
2019 |
|
Malignant tumor of colon
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, this down-regulation of REV3L also diminished colon cancer cell migration, and down-regulated MMP-2 and MMP-9.
|
29435169 |
2018 |
|
Colon Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, this down-regulation of REV3L also diminished colon cancer cell migration, and down-regulated MMP-2 and MMP-9.
|
29435169 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Among single genetic variants consistently associated with diabetes-related metabolites, two (rs174550 (FADS1), rs3204953 (REV3L)) were significantly associated with type 2 diabetes in large-scale meta-analysis for type 2 diabetes.
|
28729637 |
2017 |
|
Agenesis
|
0.010 |
Biomarker
|
disease |
BEFREE |
The analysis also provided a number of candidate genes possibly causing the developmental defects observed in PS patients, among others REV3L, a gene coding for an error-prone DNA polymerase previously associated with Möbius Syndrome with variable phenotypes including pectoralis muscle agenesis.
|
27884122 |
2016 |
|
Fanconi Anemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We detected an enrichment for variants in FA DNA damage repair pathway genes in our familial CRC cohort as 6 families carried heterozygous, rare, potentially pathogenic variants located in BRCA2/FANCD1, BRIP1/FANCJ, FANCC, FANCE and REV3L/POLZ.
|
27165003 |
2016 |
|
Squamous cell carcinoma of the head and neck
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
Our data suggest that the 'platinum' mutational signature and inactivation of REV3L may inform treatment options in patients of recurrent SCCHN.
|
26790612 |
2016 |
|
FANCONI ANEMIA, COMPLEMENTATION GROUP A (disorder)
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We detected an enrichment for variants in FA DNA damage repair pathway genes in our familial CRC cohort as 6 families carried heterozygous, rare, potentially pathogenic variants located in BRCA2/FANCD1, BRIP1/FANCJ, FANCC, FANCE and REV3L/POLZ.
|
27165003 |
2016 |
|
Malignant tumor of cervix
|
0.010 |
Biomarker
|
disease |
BEFREE |
We then established some cervical cancer cell lines with REV3L suppression or overexpression.
|
25781640 |
2015 |
|
Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, using recurrent temozolomide-refractory glioblastoma specimens, temozolomide-resistant cells, and resistant-xenograft models, we report that loss of miR-29c via c-Myc drives the acquisition of temozolomide resistance through enhancement of REV3L-mediated DNA repair and mutagenesis in glioblastoma.
|
26450587 |
2015 |
|
Osteosarcoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
As osteosarcoma patients are commonly treated with cisplatin-based chemotherapy, our aim was to investigate if REV1 and REV3L polymorphisms influence survival of osteosarcoma patients treated with cisplatin-based chemotherapy.
|
25748439 |
2015 |
|
Adult Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, using recurrent temozolomide-refractory glioblastoma specimens, temozolomide-resistant cells, and resistant-xenograft models, we report that loss of miR-29c via c-Myc drives the acquisition of temozolomide resistance through enhancement of REV3L-mediated DNA repair and mutagenesis in glioblastoma.
|
26450587 |
2015 |
|
Childhood Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, using recurrent temozolomide-refractory glioblastoma specimens, temozolomide-resistant cells, and resistant-xenograft models, we report that loss of miR-29c via c-Myc drives the acquisition of temozolomide resistance through enhancement of REV3L-mediated DNA repair and mutagenesis in glioblastoma.
|
26450587 |
2015 |
|
Cervix carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We then established some cervical cancer cell lines with REV3L suppression or overexpression.
|
25781640 |
2015 |
|
Osteosarcoma of bone
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
As osteosarcoma patients are commonly treated with cisplatin-based chemotherapy, our aim was to investigate if REV1 and REV3L polymorphisms influence survival of osteosarcoma patients treated with cisplatin-based chemotherapy.
|
25748439 |
2015 |
|
Tumor Cell Invasion
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Inactivation of Rev3 decreases cell migration and invasion, and localization of Rev3 in mitochondria increases survival and the invasive potential of cancer cells.
|
26462070 |
2015 |
|
Childhood Osteosarcoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
As osteosarcoma patients are commonly treated with cisplatin-based chemotherapy, our aim was to investigate if REV1 and REV3L polymorphisms influence survival of osteosarcoma patients treated with cisplatin-based chemotherapy.
|
25748439 |
2015 |
|
Mammary Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Rev3 expression is increased in human primary breast tumors and breast cancer cell lines.
|
26462070 |
2015 |
|
Glioblastoma Multiforme
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, using recurrent temozolomide-refractory glioblastoma specimens, temozolomide-resistant cells, and resistant-xenograft models, we report that loss of miR-29c via c-Myc drives the acquisition of temozolomide resistance through enhancement of REV3L-mediated DNA repair and mutagenesis in glioblastoma.
|
26450587 |
2015 |
|
cervical cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
We then established some cervical cancer cell lines with REV3L suppression or overexpression.
|
25781640 |
2015 |
|
Rheumatoid Arthritis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Non-HLA single nucleotide polymorphisms (SNPs) in the intergenic regions LOC389203;RBPJ, LOC100131131;IL1R1, KIAA1919;REV3L, LOC643749;TRAF3IP2, and SNPs in the intron and untranslated regions (UTR) of IRF1 and the intronic region of ICOS and KIAA1542 showed association with RA (p < 5 × 10(-5)).
|
25014791 |
2014 |
|
FANCONI ANEMIA, COMPLEMENTATION GROUP D2
|
0.010 |
Biomarker
|
disease |
BEFREE |
The genomic instability induced by Rev3 depletion seems to be related to replication stress, as it is further enhanced on aphidicolin treatment and results in increased metaphase-specific Fanconi anemia complementation group D type 2 (FANCD2) foci formation, as well as FANCD2-positive anaphase bridges.
|
23303771 |
2013 |
|
Mesothelioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Surprisingly, we found that short hairpin RNA-mediated depletion of REV3 per se suppresses colony formation of lung (A549, Calu-3), breast (MCF-7, MDA-MB-231), mesothelioma (IL45 and ZL55), and colon (HCT116 +/-p53) tumor cell lines, whereas control cell lines (AD293, LP9-hTERT) and the normal mesothelial primary culture (SDM104) are less affected.
|
22028621 |
2011 |